Spencer Pharmaceutical Announces Dr. Abderrazzak Merzouki Joins the Scientific Advisory Board and Business Advisor

BOSTON, MA--(Marketwire - October 28, 2010) -

Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announced today the addition of Dr. Abderrazzak Merzouki to join its Scientific Advisory Board as well as accepting a position as a business advisor with the company.

The management of Spencer Pharmaceutical Inc. is delighted to announce the addition of Dr. Merzouki to the Scientific Advisory Board. He brings a wealth of scientific research knowledge to the team. Dr. Merzouki is a research scientist and professor of Virology-Immunology.

He is currently teaching and lecturing at the Institute of Biomedical Engineering (Department of Chemical Engineering) at Ecole Polytechnique de Montreal since 2007 as a senior scientist where he currently manages a suite of molecular and cell biology laboratories.

“Dr. Merzouki is a molecular biologist and an immunologist with a long experience in the gene therapy area where he has performed several preclinical and clinical analysis for pharmaceutical companies involving the use of adenoviral vectors for cancer (Introgen Therapeutics Inc., USA Gencell Asia/Pacific, Japan) and DNA plasmid vectors for peripheral artery occlusive disease (Aventis Pharma, France/USA). Dr. Merzouki has an extensive expertise in the design of expressing vectors, production and purification of recombinants proteins. He developed technologies (Patents pending) for production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis,” stated Dr. Max Arella, CEO and Chairman of Spencer Pharmaceutical Inc. “We are pleased that Dr. Merzouki has accepted to serve Spencer Pharmaceutical as a scientific and business advisor. His extensive network in scientific and businesses circles in the Middle East/North Africa regions will certainly be a major asset for our company in future negotiations in this part of the world,” concluded Dr. Arella.

About Spencer Pharmaceutical Inc.

Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.

Important Information

About Forward-Looking Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company’s website does not constitute a part of this release.